Sean Bohen Biography and Net Worth

Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

What is Sean Bohen's net worth?: The estimated net worth of Sean Bohen is at least $1.82 million as of December 10th, 2024. Dr. Bohen owns 298,836 shares of Olema Pharmaceuticals stock worth more than $1,822,900 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Bohen may own. Additionally, Dr. Bohen receives an annual salary of $1,150,000.00 as CEO at Olema Pharmaceuticals. Learn More about Sean Bohen's net worth.
How old is Sean Bohen?: Dr. Bohen is currently 57 years old. There are 4 older executives and no younger executives at Olema Pharmaceuticals. Learn More on Sean Bohen's age.
What is Sean Bohen's salary?: As the CEO of Olema Pharmaceuticals, Inc., Dr. Bohen earns $1,150,000.00 per year. Learn More on Sean Bohen's salary.
How do I contact Sean Bohen?: The corporate mailing address for Dr. Bohen and other Olema Pharmaceuticals executives is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. Olema Pharmaceuticals can also be reached via phone at 650-243-5555 and via email at [email protected]. Learn More on Sean Bohen's contact information.
Has Sean Bohen been buying or selling shares of Olema Pharmaceuticals?: During the last quarter, Sean Bohen has sold $490,313.36 in shares of Olema Pharmaceuticals stock. Most recently, Sean Bohen sold 52,328 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a transaction totalling $490,313.36. Following the completion of the sale, the chief executive officer now directly owns 298,836 shares of the company's stock, valued at $2,800,093.32. Learn More on Sean Bohen's trading history.
Who are Olema Pharmaceuticals' active insiders?: Olema Pharmaceuticals' insider roster includes Sean Bohen (CEO), Cyrus Harmon (CTO), and Kinney Horn (Insider). Learn More on Olema Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Olema Pharmaceuticals?: During the last twelve months, insiders at the sold shares 15 times. They sold a total of 3,312,863 shares worth more than $42,767,106.87. The most recent insider tranaction occured on December, 17th when Director G. Walmsley Graham sold 700,761 shares worth more than $4,730,136.75. Insiders at Olema Pharmaceuticals own 19.4% of the company. Learn More about insider trades at Olema Pharmaceuticals.
Information on this page was last updated on 12/17/2024.

Sean Bohen Insider Trading History at Olema Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	52,328	$9.37	$490,313.36	298,836
11/21/2023	Sell	29,293	$14.88	$435,879.84	172,857
10/14/2021	Sell	5,000	$30.47	$152,350.00
9/27/2021	Sell	1,085	$30.07	$32,625.95
9/1/2021	Sell	871	$30.05	$26,173.55

Sean Bohen Buying and Selling Activity at Olema Pharmaceuticals

Olema Pharmaceuticals Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $6.10

$5.69

$6.21

50 Day Range

MA: $10.17

$5.79

$12.72

2 Week Range

Now: $6.10

$5.56

$16.77

Volume

1,281,874 shs

Average Volume

770,595 shs

Market Capitalization

$349.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Sean Bohen Biography and Net Worth

What is Sean Bohen's net worth?

How old is Sean Bohen?

What is Sean Bohen's salary?

How do I contact Sean Bohen?

Has Sean Bohen been buying or selling shares of Olema Pharmaceuticals?

Who are Olema Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Olema Pharmaceuticals?